Regeneron (REGN) exec says it expects to price obesity drug reasonably close to parity with therapies that do not offer cholesterol lowering benefits, according to remarks at a TD Cowen conference

Regeneron's commentary on pricing its obesity drug near parity with other therapies indicates a strategic positioning amid competitive pressures. Their exploration of acquisition opportunities suggests they are looking to bolster their portfolio, which could have implications for growth prospects and market dynamics in the biotech sector. Keep an eye on how these moves are received, as they can significantly influence investor sentiment and stock performance.